SI1891038T1 - Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja - Google Patents

Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja

Info

Publication number
SI1891038T1
SI1891038T1 SI200630177T SI200630177T SI1891038T1 SI 1891038 T1 SI1891038 T1 SI 1891038T1 SI 200630177 T SI200630177 T SI 200630177T SI 200630177 T SI200630177 T SI 200630177T SI 1891038 T1 SI1891038 T1 SI 1891038T1
Authority
SI
Slovenia
Prior art keywords
arylpyrrolidines
substituted
androgen receptor
compound
formula
Prior art date
Application number
SI200630177T
Other languages
English (en)
Slovenian (sl)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Douglas Richard Stack
Ian Roger Clemens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI1891038T1 publication Critical patent/SI1891038T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200630177T 2005-05-13 2006-05-10 Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja SI1891038T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68091105P 2005-05-13 2005-05-13
EP06759481A EP1891038B1 (en) 2005-05-13 2006-05-10 Substituted n-arylpyrrolidines as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
SI1891038T1 true SI1891038T1 (sl) 2009-04-30

Family

ID=37057376

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630177T SI1891038T1 (sl) 2005-05-13 2006-05-10 Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja

Country Status (17)

Country Link
US (1) US7807691B2 (cg-RX-API-DMAC7.html)
EP (1) EP1891038B1 (cg-RX-API-DMAC7.html)
JP (1) JP5089578B2 (cg-RX-API-DMAC7.html)
CN (1) CN101175747B (cg-RX-API-DMAC7.html)
AT (1) ATE412647T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006247738A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610183A2 (cg-RX-API-DMAC7.html)
CA (1) CA2608419A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108690T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006003432D1 (cg-RX-API-DMAC7.html)
DK (1) DK1891038T3 (cg-RX-API-DMAC7.html)
ES (1) ES2314922T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007014053A (cg-RX-API-DMAC7.html)
PL (1) PL1891038T3 (cg-RX-API-DMAC7.html)
PT (1) PT1891038E (cg-RX-API-DMAC7.html)
SI (1) SI1891038T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006124447A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617256C (en) * 2005-08-01 2014-07-15 Takeda Pharmaceutical Company Limited Cyclic amine compound
JP5241507B2 (ja) 2006-11-30 2013-07-17 武田薬品工業株式会社 環状アミン化合物
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EA017429B1 (ru) 2007-08-07 2012-12-28 Такеда Фармасьютикал Компани Лимитед Циклические аминные соединения
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
ES2488990T3 (es) 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2009133861A1 (ja) * 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
ES2551592T3 (es) * 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
US20150291596A1 (en) * 2012-11-16 2015-10-15 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
PL3122426T3 (pl) 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
EP3692028B1 (en) 2017-10-06 2023-04-26 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
CN112566666A (zh) 2018-05-14 2021-03-26 努瓦申生物公司 靶向抗癌核激素受体的化合物
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
FI3860989T3 (fi) 2018-10-05 2023-05-25 Forma Therapeutics Inc Ubikitiinispesifisen proteaasi 30:n (usp30) inhiboiminen
MA54946A (fr) 2019-02-12 2021-12-22 Radius Pharmaceuticals Inc Procédés et composés
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN114746400A (zh) * 2019-11-20 2022-07-12 南京明德新药研发有限公司 用作选择性雄激素受体调节剂的化合物
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
CA3218577A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2025160286A1 (en) * 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
US7649001B2 (en) 2002-08-12 2010-01-19 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
WO2004037784A2 (en) * 2002-10-21 2004-05-06 Irm Llc Pyrrolidones with anti-hiv activity
WO2005000795A2 (en) 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators

Also Published As

Publication number Publication date
JP2008540554A (ja) 2008-11-20
EP1891038B1 (en) 2008-10-29
CA2608419A1 (en) 2006-11-23
MX2007014053A (es) 2008-02-05
DK1891038T3 (da) 2009-01-19
US7807691B2 (en) 2010-10-05
PL1891038T3 (pl) 2009-04-30
JP5089578B2 (ja) 2012-12-05
CY1108690T1 (el) 2014-04-09
WO2006124447A3 (en) 2007-03-29
US20080176864A1 (en) 2008-07-24
ATE412647T1 (de) 2008-11-15
CN101175747A (zh) 2008-05-07
DE602006003432D1 (de) 2008-12-11
WO2006124447A2 (en) 2006-11-23
CN101175747B (zh) 2011-06-22
BRPI0610183A2 (pt) 2012-12-04
EP1891038A2 (en) 2008-02-27
PT1891038E (pt) 2008-12-02
AU2006247738A1 (en) 2006-11-23
ES2314922T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
PL1891038T3 (pl) Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
PL1902026T3 (pl) Pochodne tetrahydrokarbazolu użyteczne jako modulatory receptora androgenowego (SARM)
TN2009000189A1 (en) Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators
EA201071317A1 (ru) ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
MX2009011816A (es) Derivados de piridina.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
TNSN07384A1 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
MY151295A (en) Pyrimidyl indoline compound
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
GEP20135806B (en) Lactams as beta secretase inhibitors
MXPA05013856A (es) Agonistas del receptor sht2c para el tratamiento de diabetes y obesidad.
TW200626158A (en) Naphthaline derivatives
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
MX2010007967A (es) N-[3-bromo-2-cloro-4-(4,5-dihidro-1h-imidazol-2-ilmetil)-fenil]-m etansulfoamida como agonista parcial alfa-1 a adrenergico para el tratamiento de la incontinencia.
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
UA93951C2 (ru) Производные 2-пиридинкарбоксамида b качестве модуляторов натриевых каналов
PT1817029E (pt) Derivado isoxazólico para o alívio de dores neuropáticas